Advancements in polycaprolactone nanoparticles for targeted drug delivery in breast cancer treatment: Strategies and challenges

Next Nanotechnology Pub Date : 2025-01-01 DOI:10.1016/j.nxnano.2025.100206

Kashyak L. Sahu , Komal Naeem , Miriya R. Carson , Nabira Kanwal Nawaz , Naila Gulfam , Muhammad Zahoor

{"title":"Advancements in polycaprolactone nanoparticles for targeted drug delivery in breast cancer treatment: Strategies and challenges","authors":"Kashyak L. Sahu , Komal Naeem , Miriya R. Carson , Nabira Kanwal Nawaz , Naila Gulfam , Muhammad Zahoor","doi":"10.1016/j.nxnano.2025.100206","DOIUrl":null,"url":null,"abstract":"<div><div>Poly(ε-caprolactone; PCL) is a biodegradable and biocompatible polyester that can be suitable to develop nanoparticles for sustainable drug delivery applications and improve the efficacy of Breast cancer treatment. In this review, we summarize some latest advances in targeted delivery strategies Such as Active Targeting, Passive Targeting and Stimuli Responsive targeting for PCL-based drug carriers and explore their potential applications in delivering key anticancer agents used for effective Breast cancer therapy. We were intendent to analyse the effectiveness as well as limitations of different types of targeting delivery strategies for PCL-based drug carriers and the effectiveness of these approaches in improving drug bioavailability, reducing side effects, and achieving sustained release. By analysing current trends and narrowing knowledge gaps, this work provides insights into optimizing PCL-based systems to improve therapeutic efficacy and paves the way for innovative applications in Breast cancer treatment.</div></div>","PeriodicalId":100959,"journal":{"name":"Next Nanotechnology","volume":"8 ","pages":"Article 100206"},"PeriodicalIF":0.0000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Next Nanotechnology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2949829525000750","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Poly(ε-caprolactone; PCL) is a biodegradable and biocompatible polyester that can be suitable to develop nanoparticles for sustainable drug delivery applications and improve the efficacy of Breast cancer treatment. In this review, we summarize some latest advances in targeted delivery strategies Such as Active Targeting, Passive Targeting and Stimuli Responsive targeting for PCL-based drug carriers and explore their potential applications in delivering key anticancer agents used for effective Breast cancer therapy. We were intendent to analyse the effectiveness as well as limitations of different types of targeting delivery strategies for PCL-based drug carriers and the effectiveness of these approaches in improving drug bioavailability, reducing side effects, and achieving sustained release. By analysing current trends and narrowing knowledge gaps, this work provides insights into optimizing PCL-based systems to improve therapeutic efficacy and paves the way for innovative applications in Breast cancer treatment.

查看原文本刊更多论文

聚己内酯纳米颗粒靶向给药在乳腺癌治疗中的进展：策略和挑战

聚(ε己内酯;PCL)是一种可生物降解和生物相容性聚酯，可用于开发纳米颗粒，用于可持续的药物输送应用，提高乳腺癌治疗的疗效。本文综述了基于pcl的药物载体靶向递送策略的最新进展，包括主动靶向、被动靶向和刺激响应靶向，并探讨了它们在靶向递送关键抗癌药物方面的潜在应用，用于有效治疗乳腺癌。我们打算分析不同类型的针对pcl药物载体的靶向递送策略的有效性和局限性，以及这些方法在提高药物生物利用度、减少副作用和实现缓释方面的有效性。通过分析当前的趋势和缩小知识差距，这项工作为优化基于pcl的系统提供了见解，以提高治疗效果，并为乳腺癌治疗的创新应用铺平了道路。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Next Nanotechnology

自引率

0.00%

发文量